Kite, a Gilead Company, a biopharmaceutical company based in Santa Monica, has leased a building in the Netherlands to produce its gene-based cancer therapies in Europe, the company announced May 15.

The firm leased the 117,000-square-foot site in Hoofddorp to manufacture and deliver its personalized CAR-T cancer-fighting treatments.

The plant, expected to provide 300 jobs, is expected to open in 2020.

Gilead Sciences purchased Kite Pharma Inc. last summer for $11.9 billion. It then won federal approval for Kite’s personalized immunotherapy for adults with non-Hodgkin’s lymphoma.

In January, the Kite subsidiary paid $135 million to buy a 160,000 square-foot biotech laboratory once run by Agensys Inc. in Santa Monica to conduct cell therapy research, development and expansion.

It has also leased a 26,000 square-foot facility in Gaithersburg, Md., to work with the National Cancer Institute to develop adoptive cell therapies targeting patient-specific tumor neoantigens.

Health business reporter Dana Bartholomew can be reached at Follow him on Twitter @_DanaBart.

For reprint and licensing requests for this article, CLICK HERE.